Waun Ki Hong, MD, FACP, DMSc (Hon)

June 1, 2016

|

By

|

Estimated Read Time:

1–2 minutes

Waun Ki Hong received the 10th AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research and the 2016 ASCO Special Recognition Award, which honors an individual whose research and innovations have had a transforming and lasting effect in the areas of clinical oncology, cancer research, clinical trials, or patient advocacy activities. Dr. Hong is Professor of Medicine at The University of Texas MD Anderson Cancer Center, Houston, US.

About the Authors

Share this Article:

Waun Ki Hong, MD, FACP, DMSc (Hon)

Recent Posts

IASLC Recommendations Define Core Standards for Molecular Tumor Boards

Atezolizumab Improves PFS, but Not OS, When Added to Chemotherapy in Older Patients With Advanced NSCLC

Zipalertinib Demonstrates Promising Results for Treatment of Patients With EGFR-Mutated NSCLC After Progression

Opening Keynote to Explore Lessons From Neoadjuvant Immunotherapy Trials in Early-Stage NSCLC

COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection

Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy

Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC

No “Known” Risk Factors: The Health Consequences of Radiation Therapy

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging

No PFS, OS Benefit Seen in Final Results from PACIFIC-2

WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers

Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture

A Holistic Approach to Patient Care